Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MnP2R5l1d3SxeHnjJGF{e2G7 M1rUUlExKG6P MWq3NkBp MkfISG1UVw>? M2XUW3BwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NHP2[IszPDlyMEi3Ny=>
HT-29 NGrTVZlEgXSxdH;4bYMhSXO|YYm= MYexNEBvVQ>? NVjY[JFRPzJiaB?= M1nkNmROW09? MnrSVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 NIDNRYszPDlyMEi3Ny=>
HT-29 NFq5VWZEgXSxdH;4bYMhSXO|YYm= NYrzco84OTBibl2= M3fyTVczKGh? Mn:zSG1UVw>? NXPxc3MxWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NY\qdpBkOjR7MEC4O|M>
PC3 M4rQ[WtqdmG|ZTDBd5NigQ>? NUTzVHI{OTByIH7N NFqzWWMyKGh? M3\tbWROW09? NVfQdlJ1WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> NGLD[XEzOTl5OE[4Ny=>
PC3 NGrYfndMcW6jc3WgRZN{[Xl? MnTJNVAxKG6P NX21fXFPOSCq M13C[WROW09? MV7Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M2nwSlIyQTd6Nkiz
PC3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxMlUh|ryP MUCxJIg> NUizXnY4TE2VTx?= MkO2TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P M{fMZlIyQTd6Nkiz
HEK293 Mn3jSpVv[3Srb36gRZN{[Xl? M{CzWlExOCCwTR?= MonzPEBp M13XVWROW09? M2XQVmlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= MYeyNVU{QTNyMR?=
BT-20 MYfLbY5ie2ViQYPzZZk> M3njNVIxKM7:TR?= NHz3[lhFVVOR NF7CN2hFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= M2[zOlIyOzV|NUWx
U937 NW[0TWppSW62aXLhZ5RmemmjbDDBd5NigQ>? MlTIOVAh|ryP NV;qc2plPDhiaB?= MX\EUXNQ NIT5SIxKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= MWSyNVE1OjFyNh?=
U937 MX;BcpRq[mGldHXybYFtKEG|c3H5 MUm1NEDPxE1? MV60PEBp MWXEUXNQ NVn5RZNtTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NHvuN5EzOTF2MkGwOi=>
U937 MmfNRY51cWKjY4TldolidCCDc4PhfS=> MnnhOVAh|ryP NVnWU|dWPDhiaB?= M1eycWROW09? NIf0cFRFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NFrZU3EzOTF2MkGwOi=>
MCF-7 NVnLW3RISXW2b4DoZYd6KEG|c3H5 MoXuN|Ahdk1? MWS0JIg> MoDzSG1UVw>? NUW3OINXUW6mdXPld{BifXSxcHjh[5k> M1\TcVIxODJ6MUO0
U87MG M2GzeWtqdmG|ZTDBd5NigQ>? NH7ZW2kyKM7:TR?= MXi2JIg> M1TrOWROW09? MXXQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? NVPmN5EzOTl6NEi0NFQ>
U87MG NVvTe2dRU2mwYYPlJGF{e2G7 NXvH[VJIOSEQvF2= NFrvdYc3KGh? MmfBSG1UVw>? NFHEZZZRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> NF;5SZoyQTh2OESwOC=>
U87MG NHi1dndMcW6jc3WgRZN{[Xl? NFrB[pUyKM7:TR?= NFHFTJA3KGh? MWLEUXNQ NF34PG5Fd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= NFGye3UyQTh2OESwOC=>
U87MG NVe4blB5U2mwYYPlJGF{e2G7 MUexJO69VQ>? NGG0b3M3KGh? NVyxcWt7TE2VTx?= NFLlSIhFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? MXWxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb MojSRZV1d3CqYXf5JGF{e2G7 NH6x[nUxNjJizszN NX;PVFNUOjRiaB?= MkX2SG1UVw>? M1q3c2lv\HWlZYOgZZV1d3CqYXf5 NIPSOY4yQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NHviWVJCfXSxcHjh[5khSXO|YYm= NXPUXmdJOC5{IN88US=> M2rZSFI1KGh? NUPldnJuTE2VTx?= MoqxTY5lfWOnczDheZRweGijZ4m= M4CxZVE5OzlzOUS5
H4 NXrINW13TnWwY4Tpc44hSXO|YYm= M2HWS|AvOiEQvF2= M3Xze|I1KGh? NVXjbGpTTE2VTx?= MXzJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NXTETJJQOThyMkS1PFQ>
HeLa M4nkSGZ2dmO2aX;uJGF{e2G7 NYD4dFBoOTByIH7N M3HIcFM3KGh? M2\WdWROW09? M17q[Glv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MoPrNVc2PjN|OEW=
HeLa MofESpVv[3Srb36gRZN{[Xl? M1nBN|ExOCCwTR?= NHLxU28{PiCq MmLHSG1UVw>? MX3JcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> M4LZXVE4PTZ|M{i1
HeLa NIXIRZJHfW6ldHnvckBCe3OjeR?= MkK3NVAxKG6P NEn2OFM{PiCq NHXZS3RFVVOR MX;JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= Mof3NVc2PjN|OEW=
SYF NGrNdGZHfW6ldHnvckBCe3OjeR?= NHjGTXUyODBibl2= MX6yOEBp NH3OVHZFVVOR NHvvRoRKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NGDtZXkyPzV4M{O4OS=>
SYF NU[zT4RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xNFAhdk1? M37IdVI1KGh? MVTEUXNQ NH\KTHRKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz Mk\SNVc2PjN|OEW=
HEK293T NGDHcJFCdnSrdnnyZYwhSXO|YYm= NYTDNJVEOSCwTR?= MlnaOEBl MmH0SG1UVw>? NV[xW21mUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> MV2xO|Q5PTVyMR?=
HEK293T M4T4PWFvfGm4aYLhcEBCe3OjeR?= NW\KUZo6OSCwTR?= M1fIeFQh\A>? NGHQNlBFVVOR M3LPUGlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N MnyzNVc1QDV3MEG=
PBMC MlfoSpVv[3Srb36gRZN{[Xl? NH6yd4EyKG6P MVqxOEBl NWLHRmNFTE2VTx?= NXTGbo9bWmWmdXPld{BES1J3IHTlcpNqfHl? MnXrNVc1QDV3MEG=
PBMC MmfYSpVv[3Srb36gRZN{[Xl? MWGxJI5O MmrrNVQh\A>? NFTZNoRFVVOR MmnzSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> MXWxO|Q5PTVyMR?=
HEK293 cells NHHNU41McW6jc3WgRZN{[Xl? MnfpOVAhdk1? MWm0OUBucW5? NULzbngxTE2VTx?= NUTuRoxJUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= MVmxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MVnGeY5kfGmxbjDBd5NigQ>? NGHUdXYyODBibl2= NHnjeFE1KGh? M3rkO2ROW09? Mn3qTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> MmTINVcyOjh{NkK=
Human mixed lymphocyte MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LG[|Uhdk1? MYXEUXNQ M{TJZWlEPTB;MT62JI5ONg>? M2ftd|E3OTh3OE[1
Lewis rat lymph node cells M3XhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPwcIlLPSEQvF2= Mn\JSG1UVw>? NUnSdYhzUUN3ME2yMlYh|ryP MoL5NVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NXPobXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWflExKG6P NWfB[JBTPzJiaB?= NWLYZmU3TE2VTx?= M3PS[GlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= NUi4N5EyOTByMkG5OFg>
MRK-nu-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwOES1JJBO NU\oXWhIW0GQR1XS
OCUB-M NIjPdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTmXW1wUUN3ME21MlI1KHCP M{\5O3NCVkeHUh?=
SF539 NEPKelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmzTWM2OD1zMT62JJBO NVLwNpBbW0GQR1XS
ES4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULlSpJYUUN3ME2yNU42KHCP NHfEc4NUSU6JRWK=
RL95-2 NEjEVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyNzDwUS=> NFj1SIRUSU6JRWK=
LC-2-ad M3fyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HVXmlEPTB;NEKzJJBO NXjQVG1XW0GQR1XS
Daudi MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn35TWM2OD12M{SgdG0> M3vyOXNCVkeHUh?=
NTERA-S-cl-D1 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi3[XNKSzVyPUS0N{BxVQ>? NHPRdJlUSU6JRWK=
OS-RC-2 NGXCOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzhXHdKSzVyPU[1NkBxVQ>? NHfXNGRUSU6JRWK=
VA-ES-BJ NXzQbWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTd{MzDwUS=> NFnNVWtUSU6JRWK=
GR-ST MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPFR5F1UUN3ME24OFYheE1? MnX0V2FPT0WU
SW872 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTh2NjDwUS=> M{fF[3NCVkeHUh?=
NOS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW5TW0zUUN3ME24O|EheE1? MVPTRW5ITVJ?
MC116 NXTwU5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DKb2lEPTB;OUi1JJBO MXjTRW5ITVJ?
NCI-H1355 NVTXO2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG4bGY5UUN3ME2xMlAyKG6P NU\PV3I2W0GQR1XS
RPMI-8226 NGW2elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPIUZhKSzVyPUGuNVkhdk1? MXXTRW5ITVJ?
TE-15 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrpPYJ4UUN3ME2xMlM3KG6P M{H5NnNCVkeHUh?=
Ramos-2G6-4C10 NXTzXohiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPNOYNYUUN3ME2xMlQ3KG6P NH\wUJJUSU6JRWK=
KU812 NUnNbVZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL5TWM2OD1{LkCxJI5O NWLrN3VWW0GQR1XS
EW-1 NYnPc2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXDTWM2OD1{LkG3JI5O NES2T4RUSU6JRWK=
KS-1 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHZR25KSzVyPUKuOFUhdk1? MmrwV2FPT0WU
SK-LMS-1 NVfBZY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3rU4ZJUUN3ME2yMlQ6KG6P MULTRW5ITVJ?
TGBC1TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPCUVYzUUN3ME2yMlY6KG6P MWnTRW5ITVJ?
TE-6 NIPD[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLHTWM2OD1{Lke3JI5O MoPGV2FPT0WU
ETK-1 NHnvVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF75SVZKSzVyPUKuPFIhdk1? MV\TRW5ITVJ?
BE-13 M1jJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSweotKSzVyPUKuPVkhdk1? NIft[pBUSU6JRWK=
A3-KAW M3XNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwOUmgcm0> MUHTRW5ITVJ?
TE-10 M1iz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvtTWM2OD1|LkOgcm0> NV61UFM{W0GQR1XS
DOHH-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvyTWM2OD1|LkO1JI5O MUfTRW5ITVJ?
ES6 NXW5V29MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjlfYQ2UUN3ME2zMlQ{KG6P M2DPUnNCVkeHUh?=
OPM-2 NVTHTIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\EeIFzUUN3ME20MlE2KG6P MonwV2FPT0WU
SH-4 NIi1cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXzTWM2OD12LkO0JI5O NIfyOlhUSU6JRWK=
NB13 M{nDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnFVmRKSzVyPUSuN|Yhdk1? MWXTRW5ITVJ?
HUTU-80 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq0S|lKSzVyPUSuOFIhdk1? MV3TRW5ITVJ?
CCRF-CEM NV;hblBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwOUSgcm0> MV3TRW5ITVJ?
TGBC24TKB M3LtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TpSWlEPTB;NT61NUBvVQ>? M4fjR3NCVkeHUh?=
697 NF\KcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XFVGlEPTB;Nj6yPEBvVQ>? NELFTXhUSU6JRWK=
J-RT3-T3-5 NV\HWnQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG0[lVKSzVyPU[uOFYhdk1? Mkn0V2FPT0WU
KALS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPMTWM2OD14LkW2JI5O MoX6V2FPT0WU
no-10 M{P2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwMkmgcm0> MoTLV2FPT0WU
SK-NEP-1 NEL5UIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTIUXdiUUN3ME24Mlc6KG6P M3LX[3NCVkeHUh?=
L-540 M1H6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXEPZBKSzVyPUGwMlQzKG6P NHH3b5RUSU6JRWK=
JiyoyeP-2003 NW\MfZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5fW5KSzVyPUGwMlk1KG6P NGiwU4VUSU6JRWK=
HH NVHXclVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFzLkO5JI5O MlXkV2FPT0WU
SR M{fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tXmlEPTB;MUGuOFUhdk1? MWTTRW5ITVJ?
QIMR-WIL NX7rcWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFzLki1JI5O MnXPV2FPT0WU
A4-Fuk M3P0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDITWM2OD1zMz6xNkBvVQ>? MmXLV2FPT0WU
CESS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf2VIJKSzVyPUGzMlE{KG6P NWn4RpRQW0GQR1XS
KE-37 NGjp[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTx[3A2UUN3ME2xOk4xPyCwTR?= MnW0V2FPT0WU
SK-UT-1 NVXIOphUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXiUYlKSzVyPUG2MlgyKG6P MlrqV2FPT0WU
SIG-M5 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF5LkK1JI5O NWHpXmFCW0GQR1XS
HT NY\2NoFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn0S5IzUUN3ME2xO{43KG6P NV\Wb5JtW0GQR1XS
DEL MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTMTVdKSzVyPUG3Mlk6KG6P NUPJRohIW0GQR1XS
SK-PN-DW M3Lyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGntbG1KSzVyPUKwMlI{KG6P NGrN[5ZUSU6JRWK=
RPMI-8402 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUZ2lEPTB;MkGuO|chdk1? NEnOdlNUSU6JRWK=
RPMI-6666 NUPScXZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2NWlEPTB;MkSuOFIhdk1? NInre3NUSU6JRWK=
NCI-H720 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf5bXdKSzVyPUK1MlQyKG6P M1O0OXNCVkeHUh?=
EW-16 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsR2lEPTB;Mk[uPFchdk1? MU\TRW5ITVJ?
BL-70 NYrxNpRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnwR45KSzVyPUK4MlM5KG6P NGfSfYFUSU6JRWK=
SF126 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorKTWM2OD1|MD6zPEBvVQ>? MU\TRW5ITVJ?
BC-1 NH3OUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\JeGdKSzVyPUOxMlI3KG6P NV3uN|F1W0GQR1XS
MHH-PREB-1 NX3zWWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljGTWM2OD1|Mj60OEBvVQ>? NVXYSHlRW0GQR1XS
A101D MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjrc5FtUUN3ME2zNk43OiCwTR?= NF7lVGJUSU6JRWK=
NMC-G1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjX[5BKSzVyPUOzMlY4KG6P M4D3[nNCVkeHUh?=
LB1047-RCC NXvHXYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXCfZBIUUN3ME2zOE43QSCwTR?= NEXx[WxUSU6JRWK=
EM-2 NV3KW5BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL0N3dXUUN3ME2zPE42OyCwTR?= NX65dmtbW0GQR1XS
COLO-684 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN7Lkigcm0> NEnzcZVUSU6JRWK=
Becker NU[2T2tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki5TWM2OD12MT6wOUBvVQ>? MVrTRW5ITVJ?
BL-41 NXjCXYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jMcWlEPTB;NEOuOlYhdk1? NYLZTItvW0GQR1XS
MDA-MB-134-VI NHXCOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX30UnJ7UUN3ME20OE4xOiCwTR?= MmnoV2FPT0WU
L-363 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHSTWM2OD12ND63N{BvVQ>? MYDTRW5ITVJ?
ECC4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\WSJNKSzVyPUS0Mlc5KG6P M1T2R3NCVkeHUh?=
A388 NX60fY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR2LkiyJI5O NIO1WlBUSU6JRWK=
HEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLST21OUUN3ME20PU44QSCwTR?= Moi2V2FPT0WU
RKO M{LJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17BW2lEPTB;NUCuNlkhdk1? NEjoUlRUSU6JRWK=
KINGS-1 NGGyfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO1OpN4UUN3ME21NU42PSCwTR?= MYTTRW5ITVJ?
EB-3 NW\GV3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljBTWM2OD13Mj62O{BvVQ>? NUjlSW0{W0GQR1XS
ARH-77 NETGZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH6wU|dKSzVyPUWyMlghdk1? M2rlPXNCVkeHUh?=
GCIY NHXrPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET6VodKSzVyPUWzMlQ3KG6P MofIV2FPT0WU
NCI-H1304 NHLocndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTV5LkKyJI5O NYDKV5pVW0GQR1XS
KARPAS-299 NFu3fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zndmlEPTB;NkGuPFIhdk1? NULUXJZSW0GQR1XS
IA-LM M{nTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXpO3dKSzVyPU[4MlE{KG6P NHj5W29USU6JRWK=
GI-1 M3n2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTdyLkO5JI5O MXLTRW5ITVJ?
TE-11 NHjGRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD15Nz6xO{BvVQ>? MnOzV2FPT0WU
LS-411N Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHTR3Y1UUN3ME23O{42PyCwTR?= NGPPTmVUSU6JRWK=
no-11 NEj4WnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;qTWM2OD16Mz6yOEBvVQ>? M33LcnNCVkeHUh?=
MV-4-11 M3rOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXJc41OUUN3ME24N{44OyCwTR?= MVvTRW5ITVJ?
BV-173 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3FWHlKSzVyPUizMlk4KG6P NYT1WoFRW0GQR1XS
CMK MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTh2LkG2JI5O M4DjcHNCVkeHUh?=
LC4-1 M3LOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7WUmY3UUN3ME24Ok44OiCwTR?= NXvBcHZKW0GQR1XS
COR-L279 M2Pad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfo[41KSzVyPUi3MlI2KG6P Ml\XV2FPT0WU
NCI-H209 NHT4R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PhNWlEPTB;OEeuOFEhdk1? MXfTRW5ITVJ?
Raji M1W0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37vU2lEPTB;OEmuO|Ihdk1? Mn75V2FPT0WU
LB996-RCC NGK1b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTl|LkSzJI5O M3fmWnNCVkeHUh?=
NCI-H526 NFHxTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fjdmlEPTB;OUOuOVkhdk1? MX3TRW5ITVJ?
KGN M1XaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHjTWM2OD17Nj6yPUBvVQ>? MXnTRW5ITVJ?
MOLT-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHIRZJSUUN3ME25Ok44QSCwTR?= M3rvfnNCVkeHUh?=
PF-382 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTl4Lke5JI5O NFHGOJpUSU6JRWK=
BC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jQcmlEPTB;OUmuNVghdk1? MoLtV2FPT0WU
KARPAS-422 NW\KVllVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnzT4VKSzVyPUGwNk4xQSCwTR?= MWLTRW5ITVJ?
SBC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTUTINKSzVyPUGwO{44PSCwTR?= NVjFNohqW0GQR1XS
LC-1F MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nyfGlEPTB;MUC4MlA2KG6P MoH3V2FPT0WU
GB-1 NVK2[|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXLTWM2OD1zMEmuNFIhdk1? M3HHOHNCVkeHUh?=
SNB75 NHfTZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;WPItKSzVyPUGxPU43QSCwTR?= NUTnVYw3W0GQR1XS
BB65-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTkb|dKSzVyPUGxPU46OyCwTR?= NGnBdGxUSU6JRWK=
NCI-N87 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETpcmFKSzVyPUGyNU46QCCwTR?= NFfzUlhUSU6JRWK=
IST-MEL1 NXjJNHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF{Mj6zPEBvVQ>? Ml;hV2FPT0WU
HOP-62 NVvyUVVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPDe|RKSzVyPUGyOk45QSCwTR?= MmTYV2FPT0WU
ACN M{H0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jh[mlEPTB;MUS2Mlc2KG6P MYXTRW5ITVJ?
DMS-114 M{C2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0NmlEPTB;MUWwMlY4KG6P NVnzPGRsW0GQR1XS
MLMA M{C1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF3OT64PEBvVQ>? MWnTRW5ITVJ?
HT-144 M170Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK3ZYJKSzVyPUG2OU41OyCwTR?= NET4c29USU6JRWK=
C2BBe1 NXLPNYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vzc2lEPTB;MU[3Mlc3KG6P MnH3V2FPT0WU
L-428 M2n4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD1zN{euO{BvVQ>? MlrHV2FPT0WU
DU-4475 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH5NYkxUUN3ME2xPFcvPjhibl2= NEfNcFhUSU6JRWK=
CP67-MEL M4iy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1zOUmuN|ghdk1? NXzOV2tNW0GQR1XS
MEG-01 NWj1PXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJyMT65OkBvVQ>? MmXTV2FPT0WU
IST-SL2 M{\YNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqxc3NKSzVyPUKwPE43OyCwTR?= MnjCV2FPT0WU
ES8 NGL5fpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfSeohUUUN3ME2yNlUvQTRibl2= MnvuV2FPT0WU
COLO-800 NX;xN5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH1N|l{UUN3ME2yN|UvOjhibl2= NUHJTopUW0GQR1XS
MFH-ino MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17wT2lEPTB;MkO1Mlg1KG6P M1;jeXNCVkeHUh?=
OVCAR-4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ|Nz6yOEBvVQ>? NVz0TFhMW0GQR1XS
PSN1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj4U5JGUUN3ME2yOFIvPzFibl2= NVfIWm1WW0GQR1XS
EW-12 NGrQWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ2Mz6xJI5O MWHTRW5ITVJ?
HCC1599 NXn0[2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ4MT60O{BvVQ>? MYXTRW5ITVJ?
SJSA-1 NXPmTIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmb2ZjUUN3ME2yO|EvPDZibl2= MXPTRW5ITVJ?
ST486 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ7Nj6xOEBvVQ>? Mnf5V2FPT0WU
NOMO-1 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD1|MECuNlEhdk1? NFj4b29USU6JRWK=
MN-60 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[zfmlEPTB;M{C1MlMzKG6P MXzTRW5ITVJ?
HCC1187 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{GwZ2lEPTB;M{C3MlI2KG6P MX;TRW5ITVJ?
SW982 NFG3U5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOyUHhKSzVyPUOxOE44PSCwTR?= NIDnSJZUSU6JRWK=
LB647-SCLC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XZRmlEPTB;M{K4MlcyKG6P MmC3V2FPT0WU
HC-1 NWflO2R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPJSYlKSzVyPUOzOU42KG6P NF7KPGZUSU6JRWK=
EHEB NXrnWIJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nBS2lEPTB;M{O3MlUzKG6P M2jsUHNCVkeHUh?=
TUR M2nxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDxTWM2OD1|NkOuPVUhdk1? NH7TSZNUSU6JRWK=
LU-139 NXrkbFgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXwXWt2UUN3ME2zO|gvODJibl2= NF3xT3FUSU6JRWK=
NB1 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN6ND60OUBvVQ>? Ml3UV2FPT0WU
BB30-HNC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTucpdWUUN3ME2zPFgvOzJibl2= MnrqV2FPT0WU
HAL-01 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK4TWM2OD1|OEmuNlYhdk1? MVXTRW5ITVJ?
K5 NF73WGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jKRWlEPTB;NEGxMlM4KG6P NGCxSlVUSU6JRWK=
MZ2-MEL NGXEZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X4Z2lEPTB;NEGzMlY1KG6P MlPVV2FPT0WU
RXF393 NEezNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DheGlEPTB;NEG2MlQ2KG6P NIG3[plUSU6JRWK=
NCI-H1648 NXe5eFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXOTWM2OD12MUeuOVMhdk1? NFjNWphUSU6JRWK=
TE-12 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrmfpM3UUN3ME20N|QvOjZibl2= MYfTRW5ITVJ?
EoL-1- MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37iTWlEPTB;NEO3Mlk5KG6P NULBbmV1W0GQR1XS
JAR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pTWM2OD12M{iuOlIhdk1? Ml7vV2FPT0WU
DSH1 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLLTWM2OD12NUiuPVEhdk1? NIfi[JJUSU6JRWK=
NCI-H187 NIrIc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS4TWM2OD12NkKuPFEhdk1? MYXTRW5ITVJ?
HCE-4 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILIcnFKSzVyPUS3O{43PiCwTR?= MkLSV2FPT0WU
8-MG-BA M4nvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1RXhKSzVyPUW4NU42OiCwTR?= M1z3bHNCVkeHUh?=
KLE M1jkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jOVGlEPTB;NUi1MlIhdk1? NH:wS|BUSU6JRWK=
KNS-42 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f2Z2lEPTB;NUi2MlgyKG6P NH[yXI9USU6JRWK=
MSTO-211H M3zxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTZyOT63OEBvVQ>? Mn7mV2FPT0WU
GDM-1 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:0WpRHUUN3ME22NVQvODlibl2= M{G5dHNCVkeHUh?=
TE-1 Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjYVYVKSzVyPU[0Ok4yOiCwTR?= M{Po[XNCVkeHUh?=
BT-474 M1zIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTZ2Nz6wOkBvVQ>? NHi1N4tUSU6JRWK=
KARPAS-45 NXS1V2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHRTWM2OD14NEeuOkBvVQ>? Mo\ZV2FPT0WU
MOLT-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtR4dKSzVyPU[0O{46OyCwTR?= M4PLcXNCVkeHUh?=
KURAMOCHI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZ3Nz61NUBvVQ>? Mmq3V2FPT0WU
K-562 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\4boN7UUN3ME22OlkvPTFibl2= MmTFV2FPT0WU
EKVX MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZ5Mj63NUBvVQ>? M1;WOXNCVkeHUh?=
GAK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS4TWM2OD14N{WuN{BvVQ>? NHTZ[JNUSU6JRWK=
NCI-SNU-5 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L5NGlEPTB;NkmwMlAyKG6P M2WzNHNCVkeHUh?=
NCI-H2126 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTd{Nj64O{BvVQ>? MWTTRW5ITVJ?
CTV-1 M3\uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\UTWM2OD15NESuPUBvVQ>? M4nGRnNCVkeHUh?=
SW962 M13zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTd2OD60OEBvVQ>? M1;Hc3NCVkeHUh?=
MONO-MAC-6 NEThSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnYTWF[UUN3ME23OVYvQTNibl2= M2HSe3NCVkeHUh?=
NCI-H748 M4XqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrrZ4pjUUN3ME23OVgvQTlibl2= NUXrSGJFW0GQR1XS
NCI-H524 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M371dWlEPTB;N{iwMlc{KG6P NWXVVGx2W0GQR1XS
LS-123 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jiWmlEPTB;N{m1MlY6KG6P MlT3V2FPT0WU
NB7 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRThzND6xOEBvVQ>? MkjmV2FPT0WU
LS-1034 NIjSNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGwV3JKSzVyPUiyPE46QCCwTR?= NV3CeXJbW0GQR1XS
TE-5 NXPS[JJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnXTWM2OD16OEOuOVYhdk1? NFfKT5hUSU6JRWK=
A704 NV\ncmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTh7OT6xOUBvVQ>? NXq4dGFKW0GQR1XS
TK10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTlzNj6wN{BvVQ>? NYX2fZJpW0GQR1XS
NCI-H345 M2nqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofaTWM2OD17NEOuNlIhdk1? NGHuWFVUSU6JRWK=
CGTH-W-1 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfMfFhKSzVyPUm0PE4yOyCwTR?= NHjmW4FUSU6JRWK=
NCI-H510A NF;Jb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHkPWdKSzVyPUm4OU4yOiCwTR?= Mn:5V2FPT0WU
NCI-H1963 NWPMPG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPHToNKSzVyPUGuNFMzQTJizszN MX;TRW5ITVJ?
SCC-3 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXS[WpnUUN3ME2xMlA{PDF2IN88US=> M4ixbHNCVkeHUh?=
EW-11 M37qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW3dVlKSzVyPUGuNFg4PDNizszN MlruV2FPT0WU
CPC-N NWrXTmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjVNpRSUUN3ME2xMlA5QCEQvF2= MmDuV2FPT0WU
NCI-H1417 M4CyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC2T45KSzVyPUGuNVIzPiEQvF2= NGe2V|ZUSU6JRWK=
DG-75 NYnhflZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HGV2lEPTB;MT6xOlI5PSEQvF2= MX\TRW5ITVJ?
HD-MY-Z M1vZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwMU[0NVYh|ryP MUHTRW5ITVJ?
ATN-1 NVf5XpFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjcGlEPTB;MT6yOlIxQSEQvF2= M{XXTXNCVkeHUh?=
KM-H2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXsbYtCUUN3ME2xMlI3PDB6IN88US=> MYjTRW5ITVJ?
NCI-H2081 NUfhNFh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XvTGlEPTB;MT6yOlY{PyEQvF2= NXvzUpN5W0GQR1XS
HL-60 NXrIVJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwMk[5OVkh|ryP Ml\VV2FPT0WU
DB M1XLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2TWM2OD1zLkK3NlQzKM7:TR?= NH3F[mdUSU6JRWK=
NCI-H1522 NIXteIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;4cWJLUUN3ME2xMlI5QDh5IN88US=> M1q0OXNCVkeHUh?=
AM-38 M3y1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXQTIZqUUN3ME2xMlMxPzJizszN M2\1fnNCVkeHUh?=
NCI-H446 NVv1NmZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Sxd2lEPTB;MT6zNlEzOSEQvF2= NHnhd4JUSU6JRWK=
SU-DHL-1 M2HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwM{K4NFEh|ryP MmDKV2FPT0WU
NH-12 NGXMcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\zRmlEPTB;MT6zOlM4PCEQvF2= NV:3cIwzW0GQR1XS
DMS-79 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVi1UHdjUUN3ME2xMlM3QDZ4IN88US=> NUK4NVhlW0GQR1XS
NCI-H716 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HqRmlEPTB;MT6zPFk5PiEQvF2= MlS0V2FPT0WU
ML-2 M{T3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwNEG1Nlkh|ryP NUTReGs{W0GQR1XS
NB10 NEPaeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrvZoJlUUN3ME2xMlQ3PjN{IN88US=> NEjmNFdUSU6JRWK=
ONS-76 MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HC[GlEPTB;MT61N|U3QSEQvF2= M2PRUnNCVkeHUh?=
LOUCY MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDwTWM2OD1zLkW0OlU4KM7:TR?= MYPTRW5ITVJ?
SCLC-21H Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LPdGlEPTB;MT61PFU5OiEQvF2= NYC4PFJyW0GQR1XS
TGW NXP6SIJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvUVpBWUUN3ME2xMlY{QTd3IN88US=> MUPTRW5ITVJ?
LXF-289 NUfZXIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjvTWM2OD1zLkezNlY5KM7:TR?= M1LNU3NCVkeHUh?=
BB49-HNC M2LoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLjWnN5UUN3ME2xMlc{PTh4IN88US=> NFnPPI9USU6JRWK=
NCI-H747 M2DyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i3d2lEPTB;MT63OVM1PiEQvF2= M{HaVnNCVkeHUh?=
LU-165 NG\GdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLlTWM2OD1zLki0PVg3KM7:TR?= NHzQeYRUSU6JRWK=
OMC-1 NVPae3VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnFU4hQUUN3ME2xMlk2ODZ4IN88US=> NHTGS3JUSU6JRWK=
RCC10RGB NFjJboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjhbJNGUUN3ME2xMlk2QDF5IN88US=> NYnxb5A6W0GQR1XS
SW684 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwOU[wPVkh|ryP NW\rVogxW0GQR1XS
TE-8 NITEU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXNb|hLUUN3ME2yMlA2PTV7IN88US=> NWi2bYJxW0GQR1XS
SK-N-DZ MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1{LkGzNlc1KM7:TR?= NX3KbYFXW0GQR1XS
EVSA-T M2DHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwMUezNVUh|ryP NHHoXVVUSU6JRWK=
KASUMI-1 NHXIe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPXTWM2OD1{LkG4PFE2KM7:TR?= NFz6eXlUSU6JRWK=
NKM-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwMkW0O|Ih|ryP NUPOTIRsW0GQR1XS
CAL-148 M4W1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrGTWM2OD1{LkOzOlE1KM7:TR?= Mm\JV2FPT0WU
NCI-H64 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTvTWM2OD1{LkO0NlMzKM7:TR?= M1;2O3NCVkeHUh?=
KNS-81-FD MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrlTWM2OD1{LkO2OlIh|ryP MXnTRW5ITVJ?
KM12 NV3oOFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwNEC4N|kh|ryP NHTYVG5USU6JRWK=
SW954 NVG1Um9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwNEe3O|kh|ryP NW\xRlRIW0GQR1XS
NCI-H1395 NUT1d29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET2ZWhKSzVyPUKuOVI3PDVizszN MU\TRW5ITVJ?
DJM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHRTWM2OD1{Lk[wOlMh|ryP NWDQc4FZW0GQR1XS
COLO-668 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[2TWM2OD1{LkiyOlk2KM7:TR?= NHHzUW1USU6JRWK=
NCI-H1436 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;2NGZKSzVyPUKuPFU3OTVizszN NWfzfml6W0GQR1XS
LB2241-RCC MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z6e2lEPTB;Mj64Olg{QSEQvF2= NVTX[mdmW0GQR1XS
GT3TKB NVjYdnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vzNmlEPTB;Mj64PVA2PSEQvF2= NHTzcXFUSU6JRWK=
COLO-824 NVLPPWVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[xXWlEPTB;Mj64PVc3QCEQvF2= MWLTRW5ITVJ?
ES1 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwOEm4O|kh|ryP M4fpO3NCVkeHUh?=
LB771-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwOUC5OFYh|ryP NHHRXYVUSU6JRWK=
GI-ME-N M3nhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqxXG5KSzVyPUOuNFA6ODRizszN NH;UfXZUSU6JRWK=
NALM-6 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UTmlEPTB;Mz6wNFk{OyEQvF2= NF\Ec2JUSU6JRWK=
LU-134-A MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DEZmlEPTB;Mz6wOVQzPSEQvF2= MXzTRW5ITVJ?
DMS-153 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7hPIZ2UUN3ME2zMlA2QDJ2IN88US=> MVjTRW5ITVJ?
MZ1-PC NWfoNXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwMEmwO|gh|ryP MV3TRW5ITVJ?
NCI-H1155 NE\6UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvkTWM2OD1|LkGxOlEh|ryP M2LjPXNCVkeHUh?=
CAS-1 NHG3e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMUO3NFch|ryP NUnLdlRGW0GQR1XS
D-502MG M4\Cc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFfGlEPTB;Mz6xOFM6KM7:TR?= NX7zVWVZW0GQR1XS
NCI-H2141 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwMUe0OVIh|ryP NYD4U283W0GQR1XS
NB6 M4PtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zWZmlEPTB;Mz6xPFI2QSEQvF2= M4XWe3NCVkeHUh?=
NCCIT MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwMkG4NFkh|ryP NGiyPWVUSU6JRWK=
NB69 NFe3T4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTNwM{G4PVEh|ryP MoXoV2FPT0WU
JVM-2 NWX1cGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DXeWlEPTB;Mz6zOlQ{OyEQvF2= M2HqNHNCVkeHUh?=
K052 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHXTppkUUN3ME2zMlM4QTZ6IN88US=> NXi1NGJGW0GQR1XS
HCC2157 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnH[VBKSzVyPUOuOVMzOjhizszN NFzSOnlUSU6JRWK=
KMOE-2 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7CTpJKSzVyPUOuOVQzPDJizszN MnPOV2FPT0WU
SF268 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6TWM2OD1|LkexOVU1KM7:TR?= MkPGV2FPT0WU
CHP-126 M2X5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNwN{[0OVgh|ryP NW[1[XVLW0GQR1XS
CP66-MEL NVn6UZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwN{mwPVQh|ryP MlvmV2FPT0WU
NCI-H69 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCZnlqUUN3ME20MlAyQTN4IN88US=> NIj4fJFUSU6JRWK=
A253 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\zXFVYUUN3ME20MlAzOTBzIN88US=> M3:1OHNCVkeHUh?=
NB14 NWDJcmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[3[FdKUUN3ME20MlExPDd7IN88US=> MWjTRW5ITVJ?
NCI-H1694 M1XXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwMUOxNVIh|ryP NF23cW9USU6JRWK=
NCI-H2196 M{PMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwMUexOlkh|ryP MmfyV2FPT0WU
TE-9 M4L0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvvWWJKSzVyPUSuNVc2QDJizszN M2[5Z3NCVkeHUh?=
D-283MED M1nUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUftd|NPUUN3ME20MlE5QDRizszN MkniV2FPT0WU
OCI-AML2 NFXnd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fnT2lEPTB;ND6xPVQ5QSEQvF2= NIDINXFUSU6JRWK=
D-263MG NV\XWHFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvtNmxKSzVyPUSuNlI6PjFizszN NE\TO3FUSU6JRWK=
MPP-89 M4PQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTRwMkezNFQh|ryP MYHTRW5ITVJ?
LAMA-84 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq1N2FKSzVyPUSuN|A1OjFizszN M2HpdnNCVkeHUh?=
LB373-MEL-D NVzI[IpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRwM{[3PFkh|ryP MmPoV2FPT0WU
UACC-257 M4jDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTQTWM2OD12LkO5OVM1KM7:TR?= MlOzV2FPT0WU
MC-CAR MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT1TWM2OD12LkSzPVkh|ryP MofpV2FPT0WU
COLO-320-HSR Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTRwNES0Nlch|ryP MVvTRW5ITVJ?
P30-OHK NILRdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvkdXh[UUN3ME20MlY3PThzIN88US=> M{DkNnNCVkeHUh?=
UACC-812 NGXCdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHPdotKSzVyPUSuOlkyPjFizszN NVX5N|dTW0GQR1XS
CTB-1 M2i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwN{G1OVUh|ryP MojYV2FPT0WU
ALL-PO NIHjbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwOESwO|ch|ryP M1zENnNCVkeHUh?=
SK-MEL-2 M{jsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPTUlhKSzVyPUSuPFY6PTVizszN MXrTRW5ITVJ?
TC-YIK NV;v[WdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD12Lkm3PVQzKM7:TR?= MYXTRW5ITVJ?
NCI-H1882 MkDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrzTWM2OD13LkCyNFAyKM7:TR?= M3fVOHNCVkeHUh?=
MHH-CALL-2 NFPye5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLhfFhMUUN3ME21MlA2ODR{IN88US=> M3nOZ3NCVkeHUh?=
U-87-MG MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwMEm0OlYh|ryP M4faZXNCVkeHUh?=
NCI-H1092 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;XNnJvUUN3ME21MlI3PTV3IN88US=> MV3TRW5ITVJ?
TE-441-T NVyxUY9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXpTWM2OD13LkK3PFIh|ryP MnjnV2FPT0WU
SK-MEL-1 NEjMS29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn4TWM2OD13LkK5NFQ1KM7:TR?= NFeyc|RUSU6JRWK=
EW-22 M2Drd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPHV5dJUUN3ME21MlI6PDZ4IN88US=> MXzTRW5ITVJ?
MZ7-mel MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK2UWNkUUN3ME21MlQxPjlzIN88US=> NF;yOoxUSU6JRWK=
LP-1 NWjBUoxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwNEGyPVEh|ryP MmXVV2FPT0WU
NCI-SNU-16 NV;R[Ho5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3blFSUUN3ME21MlY1ODd2IN88US=> NXL2R|JuW0GQR1XS
LU-65 NXfPZ2M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fLO2lEPTB;NT63OlM4OyEQvF2= NF7mUJRUSU6JRWK=
CW-2 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTVwOEW5OVkh|ryP MUjTRW5ITVJ?
WSU-NHL M{CzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTVwOUWxO|Qh|ryP MVjTRW5ITVJ?
IST-MES1 NV[3UXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDi[ZNJUUN3ME21Mlk2PDR|IN88US=> MY\TRW5ITVJ?
U-266 NGHRNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES2UGpKSzVyPUWuPVgzODJizszN NFzUN5VUSU6JRWK=
TALL-1 NXe1RXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwMUS2PFgh|ryP M{XrenNCVkeHUh?=
Calu-6 NHXRXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTZwMUWzNVYh|ryP NUDzTVNxW0GQR1XS
MMAC-SF NFf6eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwMUi1OVYh|ryP NWniTpJoW0GQR1XS
NCI-H82 NUjnUml7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTZwMkC0PFkh|ryP NIS1NZNUSU6JRWK=
RS4-11 NFPIN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPJdJhyUUN3ME22MlI2QDl5IN88US=> NYTrWHp[W0GQR1XS
SNU-C2B MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPDUGtxUUN3ME22MlQxQTZ7IN88US=> M1ThV3NCVkeHUh?=
BOKU NILtcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTzZpNlUUN3ME22MlQ4PTl5IN88US=> MnXqV2FPT0WU
C8166 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTZwNUW5NVIh|ryP M2LoNXNCVkeHUh?=
D-247MG MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzocWMxUUN3ME23MlA1OzR5IN88US=> NX\3TVVCW0GQR1XS
EW-18 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS4eJRuUUN3ME23MlA4Ojl{IN88US=> M{KxPXNCVkeHUh?=
KG-1 NXrpW4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTdwNkK3N|gh|ryP MnfOV2FPT0WU
REH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvn[IlqUUN3ME23MlY5OTB7IN88US=> MmnaV2FPT0WU
U-698-M Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTdwOESzNVUh|ryP M4nLdXNCVkeHUh?=
KP-N-RT-BM-1 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfWN485UUN3ME23Mlk{ODJ7IN88US=> M2DSfHNCVkeHUh?=
MS-1 NXLrVlY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXPTWM2OD15Lkm2NFQyKM7:TR?= MmmwV2FPT0WU
SNU-C1 NFTtUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL1VpFKSzVyPUeuPVgyQTJizszN M3SwSHNCVkeHUh?=
SK-MM-2 NFXiSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRThwMk[wOlUh|ryP MnfZV2FPT0WU
LAN-6 NXHz[5dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zqfWlEPTB;OD6zNFAxOSEQvF2= MofSV2FPT0WU
NEC8 NFuwOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRThwM{C2PVEh|ryP NITo[|RUSU6JRWK=
NCI-H1770 NVLHZZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwM{iwNFIh|ryP NUHHW5Q4W0GQR1XS
D-336MG Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX1U3JLUUN3ME24MlQxOTF4IN88US=> M1jaU3NCVkeHUh?=
COLO-829 NHvicWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRThwNEi4O|kh|ryP MnzUV2FPT0WU
LS-513 M3vydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j2dGlEPTB;OD61PVU6QSEQvF2= MXPTRW5ITVJ?
YT NUHoc3M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\qW|h5UUN3ME24MlYzPDJ5IN88US=> NV\1bJljW0GQR1XS
EW-24 M2\GWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwN{[1OEDPxE1? M4nqXnNCVkeHUh?=
IST-SL1 NYnifpRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzGTWM2OD16Lki2OVQ{KM7:TR?= MnjRV2FPT0WU
CA46 NVvwS215T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fiW2lEPTB;OD65OVA6QCEQvF2= MUfTRW5ITVJ?
NCI-H1838 M{XWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5cWlEPTB;OD65PFYxOiEQvF2= NH7oOolUSU6JRWK=
NCI-H719 NUP4e457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLQcZN3UUN3ME25MlI2Ojd7IN88US=> Moi2V2FPT0WU
HCE-T NG\wVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTlwM{C4OVEh|ryP MlPPV2FPT0WU
A498 NEe3fphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\FNXdKSzVyPUmuN|YyOjRizszN MYHTRW5ITVJ?
LB831-BLC NEC5cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\hTWM2OD17Lke2OVIyKM7:TR?= NGnVUm9USU6JRWK=
SKM-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvzelc{UUN3ME25Mlg2QTZ|IN88US=> M{LIT3NCVkeHUh?=
THP-1 NWnLRohQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfOTWM2OD17Lkm2PVE5KM7:TR?= NUnSOHJvW0GQR1XS
SHP-77 M3m3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TuU2lEPTB;MUCuOFA4KM7:TR?= M1;VWnNCVkeHUh?=
EW-3 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXLZVNKSzVyPUGwMlYzQDlizszN Mln1V2FPT0WU
KY821 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHJO|dmUUN3ME2xNE44PjNizszN NWrqO|hCW0GQR1XS
NCI-SNU-1 NV2xWGkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6UVFCUUN3ME2xNU4xOjF5IN88US=> M4LST3NCVkeHUh?=
HCC2218 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOzUVNVUUN3ME2xNU4{QTh4IN88US=> Ml3UV2FPT0WU
IM-9 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLaVnZwUUN3ME2xNU42OTB4IN88US=> MWDTRW5ITVJ?
NCI-H889 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVWGlEPTB;MUGuOVMyOyEQvF2= NIjHdZNUSU6JRWK=
HDLM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfu[oVKSzVyPUGyMlQyPTlizszN Mmq1V2FPT0WU
LB2518-MEL NYDwXXpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvnVIllUUN3ME2xNk43QDF3IN88US=> NGfX[lBUSU6JRWK=
NCI-H23 NUnUWYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLtUZllUUN3ME2xN{4zPDJ3IN88US=> MU\TRW5ITVJ?
NB17 NWm2empmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nSRmlEPTB;MUOuOFU4QSEQvF2= NIrCTm5USU6JRWK=
NCI-H322M NGL2[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF2LkSwOlgh|ryP M1\5PXNCVkeHUh?=
SUP-T1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX3N|NKSzVyPUG0MlQyOyEQvF2= MonzV2FPT0WU
ES3 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPDTWM2OD1zNT6wO|A{KM7:TR?= MlfMV2FPT0WU
ES5 NX3UZpFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny0TWM2OD1zNT6wO|g4KM7:TR?= MVrTRW5ITVJ?
NCI-H1650 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LyNWlEPTB;MUWuOFk4QSEQvF2= NHuzXXJUSU6JRWK=
NCI-H226 NYDaOZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL2O49JUUN3ME2xOU45PzZ6IN88US=> NWC4W2hsW0GQR1XS
COR-L88 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF4LkOxOEDPxE1? NEfpeFZUSU6JRWK=
SCC-15 NX7INnplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF4LkO4Olkh|ryP NXPOeJRJW0GQR1XS
GOTO MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPqZXVKSzVyPUG2MlQ4QTNizszN NGm0R5pUSU6JRWK=
SIMA NFfOPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXDepVKSzVyPUG2MlQ5ODJizszN M3nIS3NCVkeHUh?=
NCI-H1299 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[0VmlEPTB;MUeuNVU6OSEQvF2= M374dXNCVkeHUh?=
NCI-H1581 NYjGTpM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkm2TWM2OD1zNz60NlE6KM7:TR?= NGXXZ5ZUSU6JRWK=
MHH-NB-11 NXzGVJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjXTpNFUUN3ME2xO{46Pjh|IN88US=> NH\5SWxUSU6JRWK=
MFM-223 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfTTI45UUN3ME2xPE4xPTN6IN88US=> M1zhR3NCVkeHUh?=
ES7 NITCe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF6LkW0N|Eh|ryP Mle1V2FPT0WU
JVM-3 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jPVmlEPTB;MUiuO|E4KM7:TR?= NWq4b|EyW0GQR1XS
RL NWXlTJBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MZWdKSzVyPUKwMlM5QCEQvF2= MmfzV2FPT0WU
EC-GI-10 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;YTWM2OD1{MT6yNFQyKM7:TR?= MXXTRW5ITVJ?
LNCaP-Clone-FGC NHzjWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnNTWM2OD1{MT62O|Y5KM7:TR?= MlHyV2FPT0WU
IMR-5 NXTZTo9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[zO4hKSzVyPUKxMlg1QTRizszN M4LkW3NCVkeHUh?=
KP-N-YS NVzCd|dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPjTWM2OD1{MT64O|Uh|ryP M{fWV3NCVkeHUh?=
Mo-T MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LieGlEPTB;MkKuNlE5PSEQvF2= M3HaSXNCVkeHUh?=
NCI-H128 NHzKfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zWVmlEPTB;MkOuOVg2OyEQvF2= MkfPV2FPT0WU
RH-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ|Lke4OlYh|ryP NV3LUmtoW0GQR1XS
NCI-H2171 NYjwPYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZbWlEPTB;MkSuNlQ5PSEQvF2= NUfk[nhwW0GQR1XS
RPMI-8866 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ4Lke0NkDPxE1? MkXXV2FPT0WU
SK-N-FI MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ5LkO4NVEh|ryP MoHXV2FPT0WU
LOXIMVI NEfSV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLJTWM2OD1{Nz64NFUyKM7:TR?= MVzTRW5ITVJ?
P31-FUJ NIPtbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPjcGJKSzVyPUOxMlU{PzRizszN MXnTRW5ITVJ?
KMS-12-PE NInxfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLxbIVRUUN3ME20PU42OzB{IN88US=> NEWyOYNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00977691 Active not recruiting Peripheral Blood Stem Cell Transplantation|Anemia Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath ) National Heart Lung and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) September 9 2009 Phase 1|Phase 2
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9 2003 Phase 2
NCT02833506 Withdrawn Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT01885689 Active not recruiting Adult Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Myelodysplastic Syndrome|Secondary Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Therapy-Related Myelodysplastic Syndrome City of Hope Medical Center|National Cancer Institute (NCI) January 8 2014 Phase 2
NCT01869114 Recruiting Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University July 8 2013 Phase 2
NCT01363752 Completed Kidney Transplantation Astellas Pharma Inc March 8 2011 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID